- support
- info@evidentic.com
- +49 (0) 30 959 99 8831
Breast neoplasm is a growth in the breast that is abnormal in nature. Neoplasms are not necessarily malignant, but diagnostic tests are usually needed to learn more about the nature of the growth and to develop an appropriate treatment plan.
Showing 1–12 of 23 results
ProductBatch | Antigen | Molecular Class | Drug Brand | Product Concentration | CoA | Quantity per vial | Storage Temperature | Expiry Date | Price from | |
---|---|---|---|---|---|---|---|---|---|---|
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
2 mg |
-80°C |
2018.06 |
212,00 € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
2 mg |
-80°C |
2018.09 |
212,00 € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
2 mg |
-80°C |
2018.09 |
212,00 € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
2 mg |
-80°C |
2018.12 |
212,00 € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
2 mg |
-80°C |
2019.03 |
212,00 € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
2 mg |
-80°C |
2019.08 |
212,00 € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
2 mg |
-80°C |
2019.10 |
212,00 € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
yes |
2 mg |
-80°C |
2021.03 |
212,00 € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
3 mg |
-80°C |
2017.09 |
267,00 € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
3 mg |
-80°C |
2018.03 |
267,00 € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
12.5 mg |
-80°C |
2024.06 |
367,00 € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
yes |
2 mg |
-80°C |
2024.07 |
212,00 € |
||
HER2 |
Biosimilar , Monoclonal Antibody |
Herzuma® |
21 mg/mL |
– |
6 mg |
tba |
tba |
356,00 € |
||
HER2 |
Biosimilar , Monoclonal Antibody |
Ontruzant® |
21 mg/mL |
– |
2 mg |
tba |
tba |
159,00 € |
||
HER2 |
Biosimilar , Monoclonal Antibody |
Kanjinti® |
21 mg/mL |
– |
6 mg |
-80°C |
2025.01 |
367,00 € |
||
HER2 |
Biosimilar , Monoclonal Antibody |
Zercepac® |
21 mg/mL |
– |
6 mg |
-80°C |
2026.08 |
367,00 € |
||
HER2 |
Biosimilar , Monoclonal Antibody |
Ogivri® |
21 mg/mL |
– |
6 mg |
-80°C |
2025.10 |
451,00 € |
||
HER2 |
Biosimilar , Monoclonal Antibody |
Trazimera® |
21 mg/mL |
– |
2 mg |
-80 °C |
2026.09 |
164,00 € |
||
HER2 |
Monoclonal Antibody |
Herceptin® |
21 mg/mL |
– |
2 mg |
-80°C |
2020.08 |
169,00 € |
||
HER2 |
Monoclonal Antibody |
Herceptin® |
21 mg/mL |
– |
2 mg |
-80°C |
2021.02 |
169,00 € |
||
HER2 |
Monoclonal Antibody |
Herceptin® |
21 mg/mL |
– |
2 mg |
-80°C |
2021.08 |
169,00 € |
||
HER2 |
Monoclonal Antibody |
Herceptin® |
21 mg/mL |
– |
2 mg |
-80°C |
2026.12 |
169,00 € |
||
HER2 |
Monoclonal Antibody |
Herceptin® |
21 mg/mL |
– |
2 mg |
-80°C |
2020.12 |
169,00 € |
Evidentic GmbH
Am Mühlenberg 10
14476 Potsdam | Germany